Literature DB >> 23276588

A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.

Sumanta Kumar Pal1, Nicholas J Vogelzang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23276588      PMCID： PMC3934560          DOI： 10.1016/j.clgc.2012.11.006

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  15 in total

1.  Toxicity of sunitinib plus bevacizumab in renal cell carcinoma.

Authors:  Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Percy Ivy; Helen X Chen; Afshin Dowlati; Robert Dreicer
Journal:  J Clin Oncol       Date:  2010-05-03       Impact factor: 44.544

Review 2.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

3.  Sorafenib in advanced clear-cell renal-cell carcinoma.

Authors:  Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski
Journal:  N Engl J Med       Date:  2007-01-11       Impact factor: 91.245

4.  Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.

Authors:  Bernard Escudier; Joaquim Bellmunt; Sylvie Négrier; Emilio Bajetta; Bohuslav Melichar; Sergio Bracarda; Alain Ravaud; Sophie Golding; Sangeeta Jethwa; Vesna Sneller
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

Authors:  Sylvie Négrier; Gwenaëlle Gravis; David Pérol; Christine Chevreau; Rémy Delva; Jacques-Olivier Bay; Ellen Blanc; Céline Ferlay; Lionnel Geoffrois; Frédéric Rolland; Eric Legouffe; Emmanuel Sevin; Brigitte Laguerre; Bernard Escudier
Journal:  Lancet Oncol       Date:  2011-06-12       Impact factor: 41.316

6.  Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.

Authors:  Ferry A L M Eskens; Maja J A de Jonge; Pankaj Bhargava; Toshiyuki Isoe; Monette M Cotreau; Brooke Esteves; Kunihiko Hayashi; Herman Burger; Maarten Thomeer; Leni van Doorn; Jaap Verweij
Journal:  Clin Cancer Res       Date:  2011-10-05       Impact factor: 12.531

7.  A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Authors:  Brian I Rini; Jorge A Garcia; Matthew M Cooney; Paul Elson; Allison Tyler; Kristi Beatty; Joseph Bokar; Tarek Mekhail; R M Bukowski; G Thomas Budd; Pierre Triozzi; Ernest Borden; Percy Ivy; Helen X Chen; Afshin Dolwati; Robert Dreicer
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

8.  Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Roberto Pili; Georg A Bjarnason; Xavier Garcia-del-Muro; Jeffrey A Sosman; Ewa Solska; George Wilding; John A Thompson; Sindy T Kim; Isan Chen; Xin Huang; Robert A Figlin
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

9.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

10.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544
View more
  2 in total

Review 1.  Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.

Authors:  David M Gill; Neeraj Agarwal; Ulka Vaishampayan
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 2.  Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.

Authors:  Kevin Zarrabi; Shenhong Wu
Journal:  Curr Oncol Rep       Date:  2018-04-02       Impact factor: 5.075
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.